We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

OptiNose Inc (OPTN) USD0.001

Sell:$1.51 Buy:$1.68 Change: $0.09 (6.12%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
Change: $0.09 (6.12%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
Change: $0.09 (6.12%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

OptiNose, Inc. is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram, is a therapeutic utilizing its exhalation Delivery System (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. Its powder EDS, which is the EDS used in its ONZETRA Xsail consists of a reusable device body incorporating a flexible mouthpiece to adjust to individual anatomic variations, and a white button piercing assembly to pierce the medication capsule.

Contact details

1020 Stony Hill Rd Ste 300
United States
+1 (267) 3643500

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$150.50 million
Shares in issue:
112.31 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Ramy Mahmoud
    Chief Executive Officer, Director
  • Anthony Krick
    Chief Accounting Officer
  • Paul Spence
    Chief Commercial Officer
  • Michael Marino
    Chief Legal Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.